| Literature DB >> 35945720 |
Yan Liu1, Linlin Ding2, Yunyan Xianyu1, Shuke Nie3, Jiying Yang3.
Abstract
BACKGROUND: The diagnosis and treatment rate of Parkinson disease (PD) with depression has a low diagnostic rate, and there is no consensus on the choice of treatment mode. This study evaluates the global research trends of scientific outputs related to depression in PD from multiple perspectives, using a bibliometric analysis and visualization tool to scientifically analyze the knowledge from the literature.Entities:
Mesh:
Year: 2022 PMID: 35945720 PMCID: PMC9351875 DOI: 10.1097/MD.0000000000029931
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1.Studies regarding depression in Parkinson disease (2012–2021).
The top 10 countries, institutions and authors in terms of publications included in WoS database during 2012–2021.
|
|
| ||||
|---|---|---|---|---|---|
| United States | 1215 (29.40) | University of Toronto | 103 (14.74) | Daniel Weintraub | 43 (15.20) |
| China | 555 (13.43) | King College London | 101 (14.45) | Pablo Martinezmartin | 42 (14.84) |
| England | 426 (10.31) | University of Pennsylvania | 83 (11.87) | Michael S Okun | 28 (9.90) |
| Italy | 422 (10.21) | University College London | 71 (10.16) | Li Zhang | 28 (9.90) |
| Germany | 339 (8.20) | Karonlinska Institutet | 65 (9.30) | Daniela Berg | 27 (9.54) |
| Canada | 299 (7.23) | University of Florida | 62 (8.87) | Paolo Barone | 26 (9.19) |
| Spain | 248 (6.00) | Harvard Medicine School | 57 (8.15) | Huifang Shang | 25 (8.83) |
| France | 232 (5.61) | Johns Hopkins University | 56 (8.01) | Paul Krack | 22 (7.77) |
| Australia | 212 (5.13) | Baylor College Medicine | 51 (7.30) | Bei Cao | 22 (7.77) |
| The Netherlands | 185 (4.48) | Columbia University | 50 (7.15) | Ruwei Ou | 20 (7.07) |
Figure 2.Visualization map of the scientific collaboration network analysis of depression in the Parkinson field from 2012 to 2021. Collaboration among countries (A), institutions (B), and authors (C).
The top 10 keywords in terms of frequency for depression in Parkinson disease field.
|
|
|
|
|
|---|---|---|---|
| 1 | Parkinson disease | 0 | 2224 |
| 2 | Depression | 0.03 | 1870 |
| 3 | Quality of life | 0.03 | 697 |
| 4 | Dementia | 0.02 | 564 |
| 5 | Nonmotor symptom | 0 | 465 |
| 6 | Prevalence | 0.02 | 462 |
| 7 | Anxiety | 0 | 457 |
| 8 | Alzheimer disease | 0 | 427 |
| 9 | Symptom | 0 | 395 |
| 10 | Disorder | 0.02 | 391 |
Figure 3.A landscape view of keyword cluster analysis generated by top 50 per slice from 2012 to 2021 (LRF = 3, LBY = 5, and e = 1.0. e = nodes, LBY = look back years, LRF = link retaining factor).
Subjects of cluster analysis (2012–2021).
|
|
|
|
|
|---|---|---|---|
| #0 Parkinson disease | 0.87 | 40 | Umbrella review, managing chronic condition, opportunity cost |
| #1 Parkinson anxiety scale | 0.886 | 37 | Parkinson disease, life emotional distress, neuropsychological |
| #2 Neuropsychiatric symptom | 0.93 | 37 | Parkinson disease, health-related quality |
| #3 Network meta-analysis | 0.956 | 33 | Resting state, theta burst, randomized controlled study |
| #4 Serotonin transporter | 0.837 | 33 | Basal ganglia, serotonin neuron loss |
| #5 Current concept | 0.903 | 32 | Current knowledge, olfactory-related cortical atrophy |
| #6 Sex disparities | 0.917 | 30 | Cardiac event, national data-linkage study, all-cause mortality |
| #7 Sleep disorder | 0.901 | 30 | Depression anxiety, emotion processing, sleep quality |
| #8 Physical activity | 0.934 | 29 | Balance training, randomized controlled pilot trial, nonmotor function |
| #9 Pentoxifylline neuroprotective effect | 0.949 | 29 | TNF-alpha inhibitory properties, features alpha-synuclein |
Figure 4.A time of the 14 largest clusters for depression in Parkinson disease (2012–2021).
Figure 5.The evolution of the research topic in different periods (2012–2021).